Trials / Completed
CompletedNCT00252798
ZD1839 (Iressa™) and Concurrent Chemo-Radiation in Patients With Locally Advanced Non Small Cell Lung Cancer
A Phase I Trial to Evaluate ZD1839(Iressa™) and Concurrent Chemo-Radiation in Patients With Locally Advanced Non Small Cell Lung Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 44 (planned)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the trial is to determine the Maximum tolerated dose, if any, of the combination of daily ZD1839 250 mg with carboplatin AUC 2 and 60 Gray (Gy) irradiation and up to 45 mg/m2 paclitaxel.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gefitinib | |
| DRUG | Carboplatin | |
| DRUG | Paclitaxel | |
| PROCEDURE | Radiation |
Timeline
- Start date
- 2002-07-01
- Completion
- 2005-10-01
- First posted
- 2005-11-15
- Last updated
- 2007-12-19
Locations
2 sites across 1 country: Australia
Source: ClinicalTrials.gov record NCT00252798. Inclusion in this directory is not an endorsement.